Jun. 24 at 11:15 AM
$HRTX Opportunity that comes once in a blue moon...
Unlike clinical-stage companies, where traders, believe in the theoretical technology or potential (legit and at times work)...
ZYNRELEF is a real, FDA-approved, rapidly growing asset worth hundreds of millions. So is APONVIE. Both of these franchises would likely generate several billions in revenue going forward. Even the distressed CINVANTI is a blessing, because it's a franchise that should still generate hundreds of millions going forward (hopefully they will reach an agreement as with the rest of the generics)
This business, with its FDA-approved franchises, is worth many hundreds of millions, especially considering its relatively small net debt. You would expect
$400M in net debt, not just
$98M, to see a valuation like this if you're calculating the current value of the revenue-generating franchises, two of them rapidly growing, less the net debt.
